Want to join the conversation?
Biopharma company $LXRX said the US FDA will need additional time to complete its review of the NDA for telotristat etiprate, an oral drug for treating carcinoid syndrome. In a notice received from the FDA, the PDUFA date for Priority Review of the drug has been extended by 3 months, from Nov. 30, 2016 to Feb. 28, 2017.
Unicorn Frappuccino. The latest hit from $SBUX. Can't wait to see how this will affect its results.
At what point should $AMZN consider a stock split? $1000 per share seems pretty high.